Iovance Financial Statements From 2010 to 2026

Iovance Biotherapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 1.1 B 1 B 433.7 M Slightly volatile Other Current Liabilities 98.9 M 94.2 M 32 M Slightly volatile Total Current Liabilities 147.7 M 140.7 M 50.3 M Slightly volatile Property Plant And Equipment Net 198.4 M 188.9 M 71.8 M Slightly volatile Non Current Assets Total 547.5 M 521.4 M 154.5 M Slightly volatile Cash And Short Term Investments 238.3 M 372.3 M 240.9 M Slightly volatile Common Stock Total Equity 4.1 K 6.9 K 4.4 K Slightly volatile Common Stock Shares Outstanding 350 M 333.4 M 122.6 M Slightly volatile Liabilities And Stockholders Equity 1.1 B 1 B 433.7 M Slightly volatile Other Current Assets 14.9 M 14.2 M 6.7 M Slightly volatile Other Stockholder Equity 3.7 B 3.6 B 1.2 B Slightly volatile Total Liabilities 241.5 M 230 M 82.6 M Slightly volatile Property Plant And Equipment Gross 241.9 M 230.3 M 82 M Slightly volatile Total Current Assets 551.8 M 525.6 M 279.1 M Slightly volatile Common Stock 15.7 K 14.9 K 6.3 K Slightly volatile Accounts Payable 33.2 M 31.6 M 12.9 M Slightly volatile Short and Long Term Debt Total 45.5 M 67 M 32.2 M Slightly volatile Current Deferred Revenue 0.86 0.9 26.1 K Slightly volatile Capital Surpluse 2.2 B 2.1 B 928.4 M Slightly volatile Short Term Debt 8.4 M 14.8 M 7.8 M Slightly volatile Property Plant Equipment 215.2 M 205 M 66.7 M Slightly volatile Other Liabilities 14.1 M 13.5 M 5.4 M Slightly volatile Net Invested Capital 548.3 M 818.1 M 374.8 M Slightly volatile Net Working Capital 384.7 M 384.9 M 267.2 M Slightly volatile Capital Stock 12.7 K 18.4 K 11.8 K Slightly volatile Capital Lease Obligations 64.2 M 65.9 M 34.3 M Slightly volatile Non Current Liabilities Other 47.4 M 75.3 M 29.9 M Slightly volatile Long Term Debt Total 800 K 900 K 982.4 K Slightly volatile
Iovance Biotherapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 52.7 M 50.1 M 13 M Slightly volatile Selling General Administrative 32.1 M 59.6 M 34.6 M Slightly volatile Other Operating Expenses 675.4 M 643.3 M 230.4 M Slightly volatile Total Operating Expenses 525.7 M 500.7 M 203.3 M Slightly volatile Research Development 340.9 M 324.7 M 143.4 M Slightly volatile Non Recurring 128 K 144 K 157.2 K Slightly volatile Preferred Stock And Other Adjustments 31.9 M 56.9 M 39.2 M Slightly volatile Interest Income 24.5 M 23.3 M 6 M Slightly volatile Net Interest Income 24.5 M 23.3 M 6.2 M Slightly volatile Reconciled Depreciation 52.7 M 50.1 M 13 M Slightly volatile Selling And Marketing Expenses 99.2 M 116.4 M 83.9 M Slightly volatile
Iovance Biotherapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Begin Period Cash Flow 218.9 M 208.5 M 85.8 M Slightly volatile Depreciation 52.7 M 50.1 M 13.4 M Slightly volatile End Period Cash Flow 73.3 M 140.4 M 79.1 M Slightly volatile Total Cash From Financing Activities 471.7 M 449.3 M 206.5 M Slightly volatile Stock Based Compensation 132.4 M 126.1 M 46.6 M Slightly volatile Issuance Of Capital Stock 441.6 M 456.9 M 415.6 M Pretty Stable
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 14.28 15.04 1.3 K Slightly volatile Dividend Yield 0.1 0.12 0.1265 Slightly volatile Days Sales Outstanding 80.25 139 60.135 Slightly volatile Average Payables 559.9 K 680.1 K 720 K Very volatile Stock Based Compensation To Revenue 0.73 0.77 43.5031 Slightly volatile Capex To Depreciation 0.28 0.29 5.687 Pretty Stable EV To Sales 13.9 14.63 1.3 K Slightly volatile Inventory Turnover 1.38 2.17 1.2043 Slightly volatile Days Of Inventory On Hand 277 174 325 Slightly volatile Payables Turnover 4.92 5.18 14.1238 Slightly volatile Research And Ddevelopement To Revenue 1.88 1.98 239 Slightly volatile Capex To Revenue 0.0737 0.0776 15.4514 Slightly volatile Cash Per Share 1.72 1.01 2.1891 Pretty Stable Days Payables Outstanding 88.47 93.12 760 Very volatile Income Quality 0.55 0.85 0.7002 Slightly volatile Intangibles To Total Assets 0.17 0.28 0.2769 Very volatile Current Ratio 3.19 3.36 13.3225 Pretty Stable Receivables Turnover 2.59 2.72 6.9362 Slightly volatile Capex Per Share 0.0669 0.0344 0.0724 Slightly volatile Revenue Per Share 0.53 0.51 0.0986 Slightly volatile Interest Debt Per Share 0.22 0.23 1.618 Slightly volatile Debt To Assets 0.0699 0.0736 14.0454 Slightly volatile Operating Cycle 387 352 390 Slightly volatile Days Of Payables Outstanding 88.47 93.12 760 Very volatile Ebt Per Ebit 1.13 1.09 1.0425 Pretty Stable Effective Tax Rate 0.0084 0.0087 0.0079 Slightly volatile Long Term Debt To Capitalization 0.0018 0.0016 0.0016 Slightly volatile Quick Ratio 2.83 2.98 13.2487 Pretty Stable Net Income Per E B T 0.79 0.89 0.9743 Slightly volatile Days Of Inventory Outstanding 277 174 325 Slightly volatile Days Of Sales Outstanding 80.25 139 60.135 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 0.86 0.93 1.0426 Pretty Stable Fixed Asset Turnover 0.94 0.9 0.1725 Slightly volatile Debt Ratio 0.0699 0.0736 14.0454 Slightly volatile Price Sales Ratio 14.28 15.04 1.3 K Slightly volatile Asset Turnover 0.17 0.16 0.0313 Slightly volatile
Iovance Biotherapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 1.5 B 1.7 B 1.9 B Slightly volatile Enterprise Value 1.5 B 1.7 B 1.8 B Slightly volatile

Iovance Fundamental Market Drivers

Iovance Upcoming Events

About Iovance Biotherapeutics Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:

How To Invest In Iovance Details

Is Iovance Stock a good investment? Details

What is Iovance Biotherapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details